The nation’s drug problem is commercial recreational pharmacology

The nation’s drug problem is commercial recreational pharmacology
Drs. Robert L. DuPont and Sharon Levy have written a brilliant paper that calls on us to view the drug problem as commercial recreational pharmacology, which they define as “the personally controlled use of psychoactive drugs that super-stimulate brain reward for pleasure.” Greater acceptance of drug use and its commercialization is exacting a toll on the nation’s public health. One example is a decline in US life expectancy, which fell three years in a row from 2016 and was driven by overdose deaths.

The researchers explain that until the 1960s, most drug use was confined to just a few drugs. But as the baby boom generation became adolescents, drug use began to be more tolerated, and an array of drugs gradually became available. This shift led to today’s opioid epidemic, marijuana legalization, and the youth vaping epidemic.

New drugs and new ways to consume them add up to huge profits for their makers. Americans spend $254 billion on alcohol, $125 billion on tobacco, and $150 billion on illicit drugs.  And thus, the acceptance of recreational pharmacology in the 60s has morphed into commercialized recreational pharmacology today.

The researchers advise “a seismic shift in our shared cultural understanding of recreational drug use from one promoted by both legal and illegal commercial interests to one based on public health science that recognizes recreational drug use as a major health risk behavior.”

We highly recommend this paper to our readers for the authors’ insights into the overall drug problem and their intelligent advice on how we can resolve it. Only the abstract is available for free, but you can “rent” the article for 48-hour online access for $7. It’s well worth the money.

Read Alcoholism and Drug Abuse Weekly abstract here.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Leave a comment

Related Posts

Major Uptick Reported in Cannabis Vaping for All Adolescents

Cannabis vaping is increasing as the most popular method of cannabis delivery among all adolescents in the U.S., as is the frequency of cannabis vaping, according to research at Columbia University Mailman School of Public Health. The study found that the frequency of vaping cannabis among adolescents from all demographic groups is reported at six

The phytochemical diversity of commercial Cannabis in the United States

The legal status of Cannabis is changing, fueling an increasing diversity of Cannabis-derived products. Because Cannabis contains dozens of chemical compounds with potential psychoactive or medicinal effects, understanding this phytochemical diversity is crucial. The legal Cannabis industry heavily markets products to consumers based on widely used labeling systems purported to predict the effects of different

What is THCP?

THCP, which is short for tetrahydrocannabiphorol and scientifically known as (-)-Trans-Δ9-tetrahydrocannabiphorol, is a natural cannabinoid and analog of THC present in varieties of cannabis. It’s thought to be 33 times more active at cannabinoid 1 (CB1) receptors than THC, causing an intense and intoxicating euphoric high. THCP’s legality is stuck between conflicting federal legislation. It’s not

Cannabis Legalization and Detection of Tetrahydrocannabinol (THC) in Injured Drivers

A recent study funded by the Canadian Institutes of Health Research found that after cannabis legalization, the prevalence of moderately injured drivers with a THC level of at least 2 ng per milliliter in participating British Columbia trauma centers more than doubled. The increase was largest among older drivers and male drivers. During the study

Scroll to Top